John R. Grainger

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

G. Acton, A. Boddy, P. Kearns, 2017, Pediatric blood & cancer.